Oliver Engert Acquires 750 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 750 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were bought at an average cost of $24.41 per share, for a total transaction of $18,307.50. Following the transaction, the insider directly owned 45,640 shares in the company, valued at approximately $1,114,072.40. This represents a 1.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Monday, March 9th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was purchased at an average price of $23.39 per share, with a total value of $23,390.00.
• On Wednesday, March 4th, Oliver Engert bought 250 shares of Enovis stock. The stock was purchased at an average cost of $25.10 per share, with a total value of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average cost of $25.50 per share, with a total value of $25,500.00.

Enovis Trading Up 4.1%

NYSE ENOV opened at $24.87 on Thursday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $40.69. The business has a 50 day moving average price of $23.94 and a 200-day moving average price of $27.91. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -1.20 and a beta of 1.46.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.Enovis’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Institutional Trading of Enovis

Several hedge funds have recently added to or reduced their stakes in the stock. McIlrath & Eck LLC grew its position in shares of Enovis by 6.9% during the 3rd quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock valued at $167,000 after acquiring an additional 357 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. Teacher Retirement System of Texas lifted its stake in Enovis by 6.1% in the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after purchasing an additional 495 shares during the last quarter. Amalgamated Bank grew its holdings in Enovis by 3.6% during the third quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock valued at $509,000 after purchasing an additional 585 shares during the period. Finally, Heritage Family Offices LLP grew its holdings in Enovis by 8.9% during the third quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock valued at $231,000 after purchasing an additional 620 shares during the period. Institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ENOV. Evercore restated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. BTIG Research boosted their price objective on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Canaccord Genuity Group lowered their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. UBS Group restated a “buy” rating and issued a $50.00 target price on shares of Enovis in a report on Monday, January 5th. Finally, Needham & Company LLC lifted their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.43.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.